Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07121946) titled 'This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma' on Aug. 12.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: LTZ Therapeutics, Inc.
Condition:
Non-Hodgkin Lymphoma Refractory/ Relapsed
DLBCL - Diffuse Large B Cell Lymphoma
Mantle Cell Lymphoma (MCL)
Follicular Lymphoma ( FL)
Marginal Zone Lymphoma (MZL)
Intervention:
Biological: LTZ-301
Biological: LTZ-301
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollmen...